Application of pharmaceutical composition to prepare medicines treating cutaneous vasculitis

A kind of technology of skin vasculitis and composition, applied in the field of medicine

Active Publication Date: 2016-02-10
施惠娟
View PDF2 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the steroid-like effect of glycyrrhizic acid, long-term oral administration of active ingredient extracts of licorice or glycyrrhizic acid and its derivatives will cause patients to have serious adverse reactions such as water and sodium retention, high blood pressure and hypokalemia.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of pharmaceutical composition to prepare medicines treating cutaneous vasculitis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023] Comparison of acute toxic effects of oxymatrine, glycyrrhizic acid and their compositions on mice

[0024] Kunming mice were randomly divided into a normal control group and a test drug group, with ten mice in each group, half male and half male. In addition to the normal control group, the test drug group was injected intraperitoneally (ip) with a large dose of oxymatrine, glycyrrhizin and the combination of the two components once, and the animals were observed continuously for 7 days, and the death time and number of animals were recorded.

[0025] The results showed that when the dose of oxymatrine was 950mg / kg, it had great toxicity, and 9 of the 10 mice died; when the dose of glycyrrhizin was 950mg / kg, 2 of the 10 mice died, while the oxidized Kushen minus: glycyrrhizin ratio 1:1 and combined dose of 950mg / kg and matrine: glycyrrhizin ratio of 2:1 and combined dosage of 950mg / kg, no animals died, oxidized matrine reduced: glycyrrhizin When the ratio of oxymatri...

Embodiment 2

[0030] Clinical observation of compound glycyrrhizin combined with oxymatrine in the treatment of allergic cutaneous vasculitis

[0031] 1 Materials and methods

[0032] 1.1 Clinical data The clinical diagnosis conforms to 40 patients with allergic cutaneous vasculitis, 20 males and 20 females, aged 20 to 50 years old, who have not received treatment within one month, and have no serious visceral diseases such as liver and kidney damage, and no Active pulmonary tuberculosis, hypertension, diabetes, cataract history, excluding pregnant and lactating women. The patients were randomly divided into four groups: oxymatrine treatment group (group A), compound glycyrrhizin treatment group (group B), oxymatrine combined with compound glycyrrhizin treatment group (group C), and control group (group D). group), ten cases in each group, half male and half male. There was no statistical difference among the four groups in terms of age, gender, and disease severity (P>0.05).

[0033] ...

Embodiment 3

[0044] Observation on the curative effect of compound glycyrrhizin combined with oxymatrine in the treatment of pigmented purpuric dermatitis

[0045] 1 Materials and methods

[0046] 1.1 Clinical data Clinical diagnosis of 10 patients with pigmented purpura-like dermatitis, 6 males and 4 females, aged 24 to 60 years old, never received systemic treatment within one month, no photosensitivity disease, no liver and kidney damage, etc. Severe visceral disease, no active tuberculosis, cataract history.

[0047] 1.2 Treatment method The patients were given intravenous infusion of oxymatrine injection 0.6g100ml / d and compound glycyrrhizin 100mg / day, both taking 6 weeks as a course of treatment, and the curative effect was judged after the course of treatment was over.

[0048] 1.3 Criteria for judging the curative effect: clinical recovery means that the skin lesions have disappeared after treatment by more than 90%; markedly effective means that the skin lesions have disappeare...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to application of oxymatrine (oxymatrine and matrine) and glycyrrhizic acid or pharmaceutically-acceptable forms of oxymatrine and glycyrrhizic acid or derivatives of oxymatrine and glycyrrhizic, a medicine containing the compositions, also comprises matrine glycyrrhizinate and oxymatrine glycyrrhizinate, and application of the compositions to prepare medicines treating cutaneous vasculitis (allergic cutaneous vasculitis, allergic purpura, erythema elevatum diutinum, acute febrile neutrophilic dermatosis, urticarial vasculitis, pustular vasculitis, polyarteritis nodosa, pyoderma gangrenosum, eosinophilic vasculitis, eosinophilic cellulitis, pigmented purpuric dermatoses, Wegener's granulomatosis, Behcet's disease, erythema nodosum, and erythema induratum).

Description

technical field [0001] The invention belongs to the field of medicine, and relates to the application of a pharmaceutical composition for preventing and treating skin vasculitis. The pharmaceutical composition contains matrine (oxymatrine, matrine, isomatrine) and glycyrrhizic acid or a pharmaceutically acceptable form of the two or derivatives of the two and the composition containing these The medicine box also includes glycyrrhizic acid matrine salt and glycyrrhizic acid matrine salt. Background technique [0002] Vasculitis is a clinicopathological process manifested by inflammation and necrosis of blood vessels and their surroundings. Histopathological changes can present a series of changes ranging from simple mild necrotizing vasculitis to granulomatous changes. Infiltrating cells can be neutrophils, lymphocytes, eosinophils, and histiocytes. Due to the different locations, sizes, scopes, degrees, and inflammatory and necrotic reactions of the involved blood vessel...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/704A61P17/00A61P9/14A61K31/4375
Inventor 施惠娟
Owner 施惠娟
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap